Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 2

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia

Authors Isabelle Wauters, Karin Pat, Johan Vansteenkiste

Published 15 June 2006 Volume 2006:2(2) Pages 175—186

Isabelle Wauters, Karin Pat, Johan Vansteenkiste

 

Respiratory Oncology Unit (Pulmonology) and Leuven Lung Cancer Group, University Hospital Gasthuisberg, Catholic University, Leuven, Belgium

 

Abstract: Anemia is frequent in cancer patients with chemotherapy, and has an important negative effect on health-related quality of life (QoL). Darbepoetin alfa belongs to a new class of erythropoietic proteins with a unique molecular structure and interesting properties compared with classic recombinant human erythropoietin. Darbepoetin alfa is effective for chemotherapy-induced anemia when administered once weekly at a dose of 2.25 µg/kg, as shown in two large phase III placebo-controlled trials in patients with solid tumors and hematological malignancies. Furthermore, it was safe and well tolerated. More recently attention has been focused on optimizing Darbepoetin alfa therapy. Front-loaded dosing was explored to accelerate the hemoglobin (Hb) response and effect on QoL, but this idea could not be confirmed in a large phase III study. Based on the prolonged half-life of Darbepoetin alfa, administration every 3 weeks was appealing. In a large phase III trial, noninferiority of administration of 500 µg every 3 weeks compared with the weekly dosing could be confirmed, both in terms of reduction of red blood cell transfusion, Hb parameters, and QoL. This schedule is very convenient for patients and caregivers as it allows synchronization of erythropoietic therapy and common chemotherapy schedules. Questions for future study are the optimal iron supplementation strategy and the effect of Darbepoetin alfa on outcome. This article reviews the clinical development of Darbepoetin alfa with emphasis on recent data.

 

Keywords: Darbepoetin alfa, erythropoietic therapy, anemia, chemotherapy-induced anemia, pharmacokinetics, clinical trials, quality of life

Download Article [PDF] 

Readers of this article also read:

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 5 December 2008

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Impact of Pharmaceutical Care interventions in the identification and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeirão Preto (SP), Brazil

Divaldo Pereira de Lyra Júnior, Nadir Kheir, Juliana Palma Abriata, Chiara Ermínia da Rocha, Cláudia Benedita dos Santos, et al

Therapeutics and Clinical Risk Management 2007, 3:989-998

Published Date: 15 January 2008

Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction

James G McMurray, Robert A Feldman, Stephen M Auerbach, Herb DeRiesthal, Neal Wilson et al

Therapeutics and Clinical Risk Management 2007, 3:975-981

Published Date: 15 January 2008